356 related articles for article (PubMed ID: 22590586)
1. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
2. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
[TBL] [Abstract][Full Text] [Related]
3. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.
DeGraff DJ; Cates JM; Mauney JR; Clark PE; Matusik RJ; Adam RM
Urol Oncol; 2013 Aug; 31(6):802-11. PubMed ID: 21924649
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
Osei-Amponsa V; Buckwalter JM; Shuman L; Zheng Z; Yamashita H; Walter V; Wildermuth T; Ellis-Mohl J; Liu C; Warrick JI; Shantz LM; Feehan RP; Al-Ahmadie H; Mendelsohn C; Raman JD; Kaestner KH; Wu XR; DeGraff DJ
Oncogene; 2020 Feb; 39(6):1302-1317. PubMed ID: 31636388
[TBL] [Abstract][Full Text] [Related]
5. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
6. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer.
Yamashita H; Amponsa VO; Warrick JI; Zheng Z; Clark PE; Raman JD; Wu XR; Mendelsohn C; DeGraff DJ
Nat Rev Urol; 2017 Feb; 14(2):98-106. PubMed ID: 27898096
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
Yee CH; Zheng Z; Shuman L; Yamashita H; Warrick JI; Wu XR; Raman JD; DeGraff DJ
Sci Rep; 2019 Jan; 9(1):270. PubMed ID: 30670749
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
9. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.
Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF
Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038
[TBL] [Abstract][Full Text] [Related]
10. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
12. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin expression in invasive urothelial carcinoma.
Sun W; Herrera GA
Ann Diagn Pathol; 2004 Feb; 8(1):17-22. PubMed ID: 15129905
[TBL] [Abstract][Full Text] [Related]
14. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
[TBL] [Abstract][Full Text] [Related]
15. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
16. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
Warrick JI; Hu W; Yamashita H; Walter V; Shuman L; Craig JM; Gellert LL; Castro MAA; Robertson AG; Kuo F; Ostrovnaya I; Sarungbam J; Chen YB; Gopalan A; Sirintrapun SJ; Fine SW; Tickoo SK; Kim K; Thomas J; Karan N; Gao SP; Clinton TN; Lenis AT; Chan TA; Chen Z; Rao M; Hollman TJ; Li Y; Socci ND; Chavan S; Viale A; Mohibullah N; Bochner BH; Pietzak EJ; Teo MY; Iyer G; Rosenberg JE; Bajorin DF; Kaag M; Merrill SB; Joshi M; Adam R; Taylor JA; Clark PE; Raman JD; Reuter VE; Chen Y; Funt SA; Solit DB; DeGraff DJ; Al-Ahmadie HA
Nat Commun; 2022 Nov; 13(1):6575. PubMed ID: 36323682
[TBL] [Abstract][Full Text] [Related]
18. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
[TBL] [Abstract][Full Text] [Related]
19. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.
Oliveira PA; Colaço A; De la Cruz LF; Lopes P; Lopes C
J Exp Clin Cancer Res; 2006 Sep; 25(3):425-32. PubMed ID: 17167984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
